
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jan 15, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG;...
Innovative Needle-Free Delivery System Provides Fast Migraine Relief SAN DIEGO, Calif. and DEERFIELD, Ill., January 13, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical...
Fourth Quarter U.S. Tarceva Sales Increased 17% on Prior Year to $137 Million Total Global Tarceva Sales for 2009 Top $1.2 Billion MELVILLE, N.Y., Jan 12, 2010 (BUSINESS WIRE) -- OSI...
MELVILLE, N.Y., Dec 29, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065,...
GAITHERSBURG, Md., Dec 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced...